03 Oct 2026, 15:02 IST
Ajanta Pharma Limited
Motilal Oswal (MOFSL) · Buy · target INR4,155
The report expects Ajanta's sales to grow 18.5% YoY driven by US and Africa segments, with DF growth of 15% YoY.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.